Preferentially increased brain volume loss in regions with high amyloid load was recently reported for a phase 3 trial of the BACE inhibitor verubecestat in mild-to-moderate Alzheimer’s disease [187]. Here, BACE1 is linked to early-onset autosomal dominant Alzheimer disease.